Increasing Funding Associated with Research and Development to Foster the Growth Global Methicilin-Resistant Staphylococcus Aureus (MRSA) Antibiotic Market

Published: Jun 2022

The global MRSA antibiotic market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). The major factors attributing to the growth of the MRSA drugs market are the rise in the global prevalence of MRSA infections and increasing private and public funding for R&D with regards to novel anti-MRSA drugs. For instance, in January 2020, Wockhardt announced regulatory approval to two antibiotics EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The drugs will target superbug MRSA, which is a leading cause of rising antimicrobial resistance. 

Browse the full report description of “Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Antibiotic Market Size, Share & Trends Analysis Report By Treatment Type (Vancomycin, Tetracycline, Linezolid, Daptomycin, and Lipopeptide), and By Distribution Channel (Online, Hospital Pharmacies, and Retail Pharmacies) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/mrsa-antibiotic-market

However, poor access to MRSA treatment and misdiagnoses of MRSA infections are the primary factors limiting the growth of the MRSA market. In addition, incorrect diagnoses of MRSA may result in inappropriate delivery and management of patient care, which in turn results in severe primary and secondary complications including death. All such factors may hinder the growth of the market during the forecast period.

Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Treatment Type

o By Distribution Channel 

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- including Merck Group., Olon Active Pharmaceutical, Pfizer Inc., Viatris Inc., and Eli Lilly and Co.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global MRSA Antibiotic Market Report Segment

By Treatment Type

  • Vancomycin
  • Tetracycline
  • Linezolid
  • Daptomycin
  • Lipopeptide

By Distribution Channel

  • Online
  • Hospital Pharmacies
  • Retail Pharmacies  

Global MRSA Antibiotic Market Report Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/mrsa-antibiotic-market